MSOP is a selective antagonist of group III metabotropic glutamate receptors (mGluRs), specifically targeting L-AP4-sensitive presynaptic mGluRs (KD = 51 μM); it is used to investigate the role of group III mGluRs in pain modulation, as it significantly blocks TBOA-induced antinociceptive effects in both the formalin and CFA pain models.